Volume 55, Issue 2, Pages (February 2009)

Slides:

Advertisements

Similar presentations

Treatment month Adjusted mean change in IPSS from baseline (ITT, LOCF) Tamsulosin

Advertisements

Volume 42, Issue 1, Pages 7-11 (July 2002)

Volume 50, Issue 3, Pages (September 2006)

Medical Management for BPH: The Role of Combination Therapy

Volume 59, Issue 2, Pages (February 2011)

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms? Mark J. Speakman European Urology Supplements

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management Michael O’Leary European Urology Supplements

Testosterone Therapy in Men With Prostate Cancer

Volume 62, Issue 5, Pages (November 2012)

Volume 67, Issue 1, Pages (January 2015)

Volume 54, Issue 6, Pages (December 2008)

Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Steven A. Kaplan,

Volume 61, Issue 6, Pages (June 2012)

Volume 60, Issue 6, Pages (December 2011)

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms? Mark J. Speakman European Urology Supplements

Prostate Cancer Epidemic in Sight?

Rowland Illing European Urology Supplements

Volume 59, Issue 2, Pages (February 2011)

Volume 46, Issue 4, Pages (October 2004)

Volume 63, Issue 1, Pages (January 2013)

Volume 60, Issue 4, Pages (October 2011)

Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey John B. McKinlay, Carol L. Link European.

Sexual Dysfunction and Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH) Raymond C. Rosen, Francois Giuliano, Culley.

Volume 52, Issue 3, Pages (September 2007)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Prostate Cancer Detection: A View of the Future

Rowland Illing European Urology Supplements

Volume 54, Issue 5, Pages (November 2008)

Volume 56, Issue 2, Pages (August 2009)

Volume 60, Issue 1, Pages (July 2011)

Volume 58, Issue 3, Pages (September 2010)

Volume 60, Issue 4, Pages (October 2011)

Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening? Bob Djavan European.

Volume 61, Issue 3, Pages (March 2012)

Volume 68, Issue 4, Pages (October 2015)

Volume 52, Issue 4, Pages (October 2007)

Prostate Cancer Epidemic in Sight?

Volume 64, Issue 2, Pages (August 2013)

Yuanshan Cui, Yong Zhang European Urology

Volume 71, Issue 4, Pages (April 2017)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 70, Issue 6, Pages (December 2016)

Relationship between Lower Urinary Tract Symptoms Frequency Assessed by the IPSS and Bothersomeness (SPI) among Men Older than 50 Years Old P. Perrin,

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Classification of Male Lower Urinary Tract Symptoms Using Mathematical Modelling and a Regression Tree Algorithm of Noninvasive Near-Infrared Spectroscopy.

Richard C. Harkaway European Urology Supplements

Volume 50, Issue 3, Pages (September 2006)

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Volume 54, Issue 6, Pages (December 2008)

When to Treat the Prostate, the Bladder, or Both?

Volume 53, Issue 6, Pages (June 2008)

What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice? François Desgrandchamps European Urology.

European Urology is “Your” Journal

The Start-Up of the Platinum Journal: A Fascinating Challenge

Martin Michel, Jean de la Rosette European Urology Supplements

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Profile of Silodosin European Urology Supplements

The Benefits of Dual Inhibition of 5α Reductase

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

C.G Roehrborn, T McNicholas European Urology Supplements

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms? Mark J. Speakman European Urology Supplements

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Volume 51, Issue 5, Pages (May 2007)

Michael Marberger European Urology Supplements

Vassilios Tzortzis, Stavros Gravas, Jean J.M.C.H. de la Rosette

Presentation transcript:

Volume 55, Issue 2, Pages 461-471 (February 2009) The Influence of Baseline Parameters on Changes in International Prostate Symptom Score with Dutasteride, Tamsulosin, and Combination Therapy among Men with Symptomatic Benign Prostatic Hyperplasia and an Enlarged Prostate: 2-Year Data from the CombAT Study Claus G. Roehrborn, Paul Siami, Jack Barkin, Ronaldo Damião, Edgardo Becher, Bernardino Miñana, Vicenzo Mirone, Ramiro Castro, Timothy Wilson, Francesco Montorsi European Urology Volume 55, Issue 2, Pages 461-471 (February 2009) DOI: 10.1016/j.eururo.2008.10.037 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Adjusted mean change in International Prostate Symptom Score (IPSS) from baseline, by visit and by treatment group, for baseline prostate volume tertiles: (a) Prostate volume 30–<42cm3; (b) prostate volume 42–<58cm3; (c) prostate volume ≥58cm3. ITT=intent to treat; LOCF=last observation carried forward. * p<0.05 combination versus dutasteride. ** p<0.01 combination versus dutasteride. *** p<0.001 combination versus dutasteride. † p<0.05 combination versus tamsulosin. †† p<0.01 combination versus tamsulosin. ††† p<0.001 combination versus tamsulosin. ‡ p<0.05 dutasteride versus tamsulosin. ‡‡ p<0.01 dutasteride versus tamsulosin. ‡‡‡ p<0.001 dutasteride versus tamsulosin. European Urology 2009 55, 461-471DOI: (10.1016/j.eururo.2008.10.037) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 Adjusted mean changes in International Prostate Symptom Score (IPSS) from baseline to month 24 (a) by prostate volume and (b) by prostate-specific antigen (PSA) tertiles. Adjusted mean changes in maximum urinary flow rate (Qmax) from baseline to month 24 (c) by prostate volume and (d) by PSA tertiles. ITT=intent to treat; LOCF=last observation carried forward. * p<0.05 combination versus dutasteride. ** p<0.01 combination versus dutasteride. *** p<0.001 combination versus dutasteride. †† p<0.01 combination versus tamsulosin. ††† p<0.001 combination versus tamsulosin. ‡‡ p<0.01 dutasteride versus tamsulosin. ‡‡‡ p<0.001 dutasteride versus tamsulosin. European Urology 2009 55, 461-471DOI: (10.1016/j.eururo.2008.10.037) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 3 (a) Adjusted mean changes in International Prostate Symptom Score (IPSS) from baseline to month 24 by previous treatment status; (b) adjusted mean changes in maximum urinary flow rate (Qmax) from baseline to month 24 by previous treatment status. ITT=intent to treat; LOCF=last observation carried forward; BPH=benign prostatic hyperplasia. * p<0.05 combination versus dutasteride. ** p<0.01 combination versus dutasteride. *** p<0.001 combination versus dutasteride. ††† p<0.001 combination versus tamsulosin. ‡‡ p<0.01 dutasteride versus tamsulosin. ‡‡‡ p<0.001 dutasteride versus tamsulosin. European Urology 2009 55, 461-471DOI: (10.1016/j.eururo.2008.10.037) Copyright © 2008 European Association of Urology Terms and Conditions